Sequence: RQIKIWFQNRRMKWKK
| Experiment Id | EXP001539 |
|---|---|
| Paper | Intracellular delivery of antiviral shRNA using penetratin-based complexes effectively inhibits resp |
| Peptide | Penetratin (PEN) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Not reported (penetratin:plasmid molar ratio 20:1; 50 µL/well used in apoptosis assays) |
| Rna Concentration | Not reported |
| Mixing Ratio | molar ratio 20:1 (penetratin:plasmid) |
| Formulation Format | noncovalent CPP/DNA complexes (electrostatic) |
| Formulation Components | Penetratin + RSV F-shRNA plasmid (pGFP-V-RS) |
| Size Nm | 164.00 |
| Zeta Mv | 8.70 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549 (human lung epithelial carcinoma) infected with RSV A2 (MOI 0.1) |
| Animal Model | |
| Administration Route | |
| Output Type | Apoptosis-related readouts (DNA fragmentation gel; PI staining; caspase 3/7 activity) |
| Output Value | Reduced DNA fragmentation and apoptotic morphology; caspase 3/7 activity significantly reduced vs untreated RSV-infected cells |
| Output Units | |
| Output Notes | In RSV-infected A549 cells, penetratin-F-shRNA mitigated apoptosis markers and reduced caspase 3/7 activity; GFP microscopy confirmed successful transfection. |
| Toxicity Notes | No penetratin/shRNA-specific toxicity reported in cell viability assays (HEp-2); A549 data focus on apoptosis markers during infection. |
| Curation Notes |